TargetMol

Atezolizumab

Product Code:
 
TAR-T9902
Product Group:
 
Primary Antibodies
Supplier:
 
TargetMol
Antibody Clonality:
 
Monoclonal
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9902-1mg1mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9902-5mg5mg£507.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9902-10mg10mg£711.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
CAS:
1380723-44-3
Formula:
0
Molecular Weight:
145 kDa
Pathway:
Apoptosis; Immunology/Inflammation; Cell Cycle/Checkpoint; Autophagy
Purity:
0.98
SMILES:
0
Target:
Apoptosis; PD-1/PD-L1; Autophagy

Documents

References

Zheng Y, et al. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered. 2017 Jul 4;8(4):367-373. Deng R, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8(3):593-603. Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. Inman BA, et al. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1886-1890.